[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atherosclerosis-of-extremities\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atherosclerosis-of-extremities":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100421926","phase-3-low-dose-colchicine-in-patients-with-peripheral-artery-disease-to-address-residual-vascular-risk-100421926",false,"NCT04774159","Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk","Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk: A Randomized Trial","LEADER-PAD","Inclusion criteria:\n\n1. Age \\> 18 years\n2. Symptomatic atherosclerotic LE PAD fulfilling at least one of the following:\n\n   a. Intermittent claudication with ankle\u002Farm blood pressure ratio\\* (ABI ≤ 0.90) or artery stenosis ≥ 50% plus one of i. \\>1 vascular bed affected by atherosclerosis ii. Diabetes iii. Heart failure iv. Chronic kidney disease (eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m2)\n\n   b. Rest pain (mostly in foot) OR necrosis of limb OR gangrene of limb (corresponding to either Fontaine stages 3 or 4 OR Rutherford Classification categories 4 to 6). All must have an ankle\u002Farm blood pressure ratio\\* (ABI ≤ 0.90) OR artery stenosis ≥ 50%.\n\n   \\* In cases of incompressible ankle arteries, the presence of toe pressure ≤ 60 mm Hg or toe-brachial index ≤ 0.70 is acceptable\n\n   c. Revascularization defined as limb bypass surgery or endovascular revascularization procedures (irrespective of the specific device used), including percutaneous transluminal angioplasty\u002Fstent of iliac or infra-inguinal arteries or extra-anatomical bypass surgery\n\n   d. Leg or foot amputation for arterial vascular indications\n3. Written or verbal informed consent from the patient\n\nExclusion Criteria:\n\n1. Contraindication to colchicine\n2. Long term requirement for colchicine for another clinical indication\n3. Active diarrhoea\n4. eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n5. Cirrhosis or severe chronic liver disease\n6. Woman who is pregnant, or breast-feeding or of child-bearing potential not protected by reliable contraception or is planning conception during the study\n7. Current or planned long term use of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics (with the exception of azithromycin)\n8. Patients who are deemed unlikely to return for follow-up\n9. Patients with life expectancy \\\u003C 1 year","ALL","18 Years",{"count":20,"type":21},6150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with symptomatic peripheral artery disease.",[27,28,29],"Peripheral Arterial Disease","Atherosclerosis of Extremities","Inflammation",[31,32,33,34,35],"Acute limb ischemia","Myocardial Infarction","Stroke","Cardiovascular death","Mortality","RECRUITING","2026-03-20",{"date":39,"type":40},"2026-03-24","ACTUAL",{"date":42,"type":40},"2021-05-06",{"date":44,"type":21},"2029-12",{"name":46,"class":47},"Population Health Research Institute","OTHER",70]